RSS Feeds
Search

Press releases

Press releases

Displaying 1..1 of 1 - per page
Order by
Desitin and G2M Cancer Drugs sign development agreement on novel cancer treatment
G2M Cancer Drugs AG and Desitin Arzneimittel GmbH announced today that they have entered into an agreement to develop an innovative formulation for the histone deacetylase (HDAC) inhibitor G2M-777 for cancer treatment. More
Displaying 1..1 of 1 - per page
Order by

Related Reports

Market Research Reports provided by reports.iptechex.com
US Oncology, Inc.: SWOT Analysis & Company Profile
Dec 2010 - 19 pages - $99
Leukemia and Types of Leukemia Therapy Area Pipeline Report
Nov 2010 - 1302 pages - $1,495
The Cancer and Leukemia Group B – Developmental Therapeutics Review – Q4 2010
Nov 2010 - 40 pages - $500
T-Cell Leukemia - Pipeline Review, Q1 2011
Jan 2011 - 20 pages - $500
Northern Italy Leukemia Group – Developmental Therapeutics Review – Q4 2010
Dec 2010 - 27 pages - $500
US Oncology, Inc. - SWOT Analysis
Nov 2010 - 26 pages - $125
Supportive Care in Oncology Market Forecast
Nov 2009 - $15,200
Therapeutic Advances in Childhood Leukemia Consortium – Developmental Therapeutics Review – Q4 2010
Dec 2010 - 35 pages - $500
Japan Adult Leukemia Study Group – Developmental Therapeutics Review – Q1 2011
Mar 2011 - 55 pages - $500
Japan Adult Leukemia Study Group – Developmental Therapeutics Review – Q4 2010
Dec 2010 - 56 pages - $500
More Related Market Research Reports >>>

Your selection

Industry sector
Biotechnology del
Therapeutic target
Oncology del
Leukemia del
Year
2003 del

Browse By

Industry sector
Assay systems
Diagnostic test systems
Gene therapy
Human diagnostics
Human therapeutics
Manufacturing
Nanotechnology
Other
Research supplies
Stem cells
Therapeutic target
Acute myeloid leukemia
Multiple myeloma
Myelodysplastic syndrome
Paget's disease

Clients in focus...

Get the Flash Player to see this rotator.

© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us